When facing advanced stomach or esophageal junction cancer, the goal of treatment is to shrink the tumor and improve long-term survival. A large review of 74 trials looked at how adding immune checkpoint inhibitors (medicines that help the immune system attack cancer) to standard chemotherapy changes these outcomes.
The data shows that combining these immune therapies with chemotherapy leads to a much higher rate of pathological complete response, which means the cancer is no longer visible in tissue samples. Patients also saw better overall survival and event-free survival when this combination was used in perioperative settings. Some specific combinations, like adding anti-angiogenic therapy, also showed increased response rates.
While the results are promising, the evidence is not equal for every treatment. While the combination of immune inhibitors and chemotherapy has the most established evidence, other combinations like those involving radiation or specific hormone therapies have much less data. Because some of these newer combinations have been tested in only a few trials, doctors still need more information to know exactly how they perform compared to standard care.
